The ArtixASCEND Study
Not Applicable
Not yet recruiting
- Conditions
- Acute Lower Limb Arterial Occlusion
- Registration Number
- NCT07135895
- Lead Sponsor
- Inari Medical
- Brief Summary
This study is a post-market, prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 330
Inclusion Criteria
- Age ≥ 18 years
- Acute symptom duration ≤ 14 days
- Lower limb arterial occlusion below inguinal ligament
- Target vessel size between 3 mm and 8 mm
- Rutherford category I, IIa, or IIb
- Informed consent is obtained from either patient or legally authorized representative (LAR) per Institutional Review Board/Ethics Committee requirements
Exclusion Criteria
- Life expectancy < 6 months
- Prior major amputation in the target limb
- Prior minor amputation in the target limb within the past 6 months or is not completely healed or cannot bear weight
- Non-thrombotic occlusion secondary to dissection, vasculitis, or target vessel trauma
- Treatment of the index event in the target vessel with any other endovascular thrombectomy/aspiration or open surgical method prior to Artix procedure
- Part of a vulnerable population (e.g., currently pregnant, breastfeeding or incarcerated) per local definitions
- Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
- Unable to tolerate antiplatelet therapy
- Inability to anticoagulate the patient with heparin, enoxaparin or other parenteral antithrombin, or known to have uncorrected bleeding disorders (e.g., gastro-intestinal ulcer, menorrhagia, liver failure, heparin-induced thrombocytopenia (HIT))
- Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., contraindication to use of Artix per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)
- Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Primary Effectiveness Endpoint Immediately Following Index Procedure Revascularization rate post-index procedure of target treatment area determined by an independent core lab.
Primary Safety Endpoint 48 Hours Periprocedural (within 48 hours) Artix Thrombectomy System-related major bleeding rate adjudicated as causal to the study device as determined by an independent Medical Monitor.
- Secondary Outcome Measures
Name Time Method Distal embolization SAEs Intra-procedure All-cause mortality 1-month follow-up visit Limb salvage 1-month follow-up visit Freedom from major amputation of the index limb
Amputation-free survival 1-month follow-up visit Freedom from major amputation and all-cause mortality